SCHEMBL15545929

SCHEMBL15545929

COc1ccc(C(=O)c2cc(CC(=O)O)c(-c3ccccc3)s2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
RXFP1 Q9HBX9 1/20 0.63
MAPT P10636 4/20 0.56
CNR1 P21554 1/20 0.51
CNR2 P34972 1/20 0.51
ALDH1A1 P00352 3/20 0.49
HTT P42858 1/20 0.49
LMNA P02545 2/20 0.48
HPGD P15428 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
KDM4E B2RXH2 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PTGDR2 Q9Y5Y4 4/20 0.46
MMP2 P08253 3/20 0.44
MMP12 P39900 3/20 0.44
MMP9 P14780 2/20 0.44
ADORA3 P0DMS8 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15546759 0.95 KMT2A (0.66) MEN1KMT2ARXFP1MAPTCNR1
SCHEMBL15545703 0.95 RXFP1 (0.69) MEN1KMT2ARXFP1MAPTCNR1
SCHEMBL16893534 0.91 MEN1 (0.53) MEN1KMT2ARXFP1MAPTCNR1
SCHEMBL15545762 0.90 RXFP1 (0.62) MEN1KMT2ARXFP1MAPTCNR1
SCHEMBL15545878 0.90 RXFP1 (0.75) MEN1KMT2ARXFP1MAPTCNR1
SCHEMBL16893399 0.88 MEN1 (0.55) MEN1KMT2ARXFP1MAPTALDH1A1
SCHEMBL15545702 0.87 MEN1 (0.62) MEN1KMT2ARXFP1MAPTCNR1
SCHEMBL15546402 0.87 MEN1 (0.50) MEN1KMT2ARXFP1MAPTCNR1
SCHEMBL16893446 0.87 MAPT (0.57) MEN1KMT2ARXFP1MAPTALDH1A1
SCHEMBL15545905 0.87 RXFP1 (0.59) MEN1KMT2ARXFP1MAPTCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US claimed
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP claimed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US claimed
EP-2875010-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES Metabrain Research (FR) 2015-05-27 EP claimed
WO-2014013181-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2014-01-23 WO claimed
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US disclosed
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US disclosed
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US disclosed
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP disclosed
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP disclosed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US disclosed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US disclosed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES SLC5A2, SLC5A1, TPMT MEN1 4184/4885KMT2A 4602/4885RXFP1 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.